Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesWilliam J. Sandborn, Brian G. Feagan, Séverine Vermeire et al.|The Lancet|2023Cited by 350
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, Séverine Vermeire, Miles Sparrow et al.|Journal of Crohn s and Colitis|2021Cited by 34
968a: ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALSWilliam J. Sandborn, Brian G. Feagan, Séverine Vermeire et al.|Gastroenterology|2022Cited by 8
DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT IIWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Journal of Crohn s and Colitis|2019Cited by 5
P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)Walter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Inflammatory Bowel Diseases|2019Cited by 4